Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

Harry .... you seem to have gone very quiet ...... trust you are not beginning to doubt that cynic is a total arsehole after all! ...... that said, i confess to being surprised myself at the current short-lived nature of the sp surge.

cynic
Harry's gone to Florence so his offline.

well i trust he (and you) have acted prudently

i would guess an awful lot haven't! ..... sp now well below opening and 20 million traded against 2.5 norm

actually finished with 41.5 million traded and at the bottom of it's range today!

having been told that i talked total rubbish - often true, but certainly not always - about the perils of this share, i shall just say that i for one will AVOID and think others might be well advised to follow suit!

Totally agree with Cynic in so far that the s/p of the vast majority of micro caps are determined by one variable and that is MOMENTUM fed by volume traded. ..@+ J

this is doing a repeat of last year, pump pump pump, it goes to 6p and then bang.. the news is not whats expected and poor buggers see shares at 1.5p again

if PIs have got hammered hard enough, there may be a worthwhile point to buy (and sell) before the promised announcement ...... something south of 1.8p might be a price to start looking to buy

curiouser and curiouser, said Alice, as she disappeared down the rabbit hole ....... sp down another large slug this morning (about 25%) ...... someone who e-mailed out a Buy note to 40,000 potential punters is either about to retire in style or has lost his shirt ...... and of course Cynic was talking total bollox when he advocated great caution, wasn't he!

Cynic you know i .,and many others would never think that of you!!!!

aaahhh! i am deeply touched (kiss, kiss!) ...... the cap primarily fits someone who is apparently in Florence at the mo

It is amazing that a rumour of a new deal was spresd far and wide just before the publishing of results that show widening losses.

How low would this be now if the rumour had not been spread?

!LONDON (AFX) - AIM-listed drug discovery company Henderson Morley PLC reported a widened first-half pretax loss but said it will continue to seek new opportunities to grow revenues by focusing on both human and animal health."

Haystack
This is true but so is this below; the sp will recover when there is more news. Still holding.


HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), notes
the movement in the Company's share price today.

The Company is able to confirm that it is in a late stage of negotiations with an
AIM-listed life sciences company. This proposed collaboration may lead to the
grant of a licence in respect of another project from Henderson Morley's product
portfolio. A further statement will be made in this respect at the appropriate
time.

In fact the last time there was 'more news' about a deal the price fell as the news wasn't as good as expected. These types of deals take years to generate real profit. There is usually a product development phase first. It make well turn out to be a good company long term, but at the moment it is just sentiment driven as profits are a long, long way off.

Cynic - your posts are just a noise.

you mean like the warning bell? ...... you put your money where you like; if HML takes your fancy, then good luck to you, but be prepared to take a bath (even if, somewhat against the odds, it doesn't happen)

Sector
Biotech

Contact
Andrew Knight.
0121 442 4600


Henderson Morley has had an active month - something reflected in a n ear doubling of its share price.. The group has revealed it is in talks with a life sciences company and also unveiled interim figures.
The company confirmed on 12th January that it was in the late stage of negotiations with an AIM-listed life sciences company, the proposals of which, could lead to the grant of a licence in respect of another project from Henderson Morley's product portfolio. A further statement is expected in due course.
Meanwhile, interim numbers for the six months to 31st October were published on 16th January and showed a retained loss of 434,238 pounds, up from 352,204 pounds - a performance very much inline with expectations.
The company has now completed the Cutanea Licence Agreement for new applications of ICVT for the treatment of dermatological conditions in humans, including skin warts, verrucae and molluscum contagiosum. The Licence is an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the deal, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter. The Amistad License Agreement is for a new application of ICVT for the topical treatment of genital and labial herpes and certain other dysplasias.
With further details regarding the potential agreement with the life sciences company also a possibility in the short term, we expect the exciting pace of newsflow to continue. We continue to believe that the share price doers not reflect what is already known at a corporate level and will be publishing a new formal valuation shortly.
*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.
Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.


http://www.bishopsgatecommunications.com/ourClients.htm

Morning
On the move, could we have news today
keith

kkeith2000
Tipped by brokers as under valued 6p IMO short term.

Driver, How do you know this?

Looks like RNS Today.